NovoCure Loses Major Holder as CII Reports Zero Shares in Amended 13G

Rhea-AI Filing Summary

Schedule 13G/A amendment highlights: Capital International Investors (CII) reports beneficial ownership of 0 shares of NovoCure Ltd. (NVCR) common stock as of the event date 06/30/2025. This represents 0.0 % of the issuer’s 111,485,634 outstanding shares. All voting and dispositive powers—sole or shared—are now listed as zero.

The filing classifies CII as an investment adviser (IA) under Rule 13d-1(b). The certification confirms the shares were held in the ordinary course of business and not for the purpose of influencing control. CII’s exit moves its ownership below the 5 % reporting threshold and effectively eliminates a prior institutional position in NovoCure.

Investor takeaway: A complete liquidation by a large asset manager can signal changing sentiment and may increase free float, potentially adding near-term supply to the market and reducing perceived institutional sponsorship. However, no other financial metrics or strategic updates for NovoCure are provided in this document.

Positive

• None.

Negative

• Capital International Investors has fully liquidated its position in NovoCure, reducing its ownership to 0 shares (0.0 %).
• Loss of a prominent institutional holder could dampen investor confidence and add selling pressure.

Insights

Securities Analyst

TL;DR – CII has sold its entire NVCR stake, removing a significant institutional holder.

CII’s Schedule 13G/A shows zero ownership, implying a full exit from NovoCure. Such divestments can be interpreted as negative for sentiment, especially given the firm’s scale and historically long-term investment horizon. While the filing does not disclose sale timing or price, the absence of any voting or dispositive power confirms no remaining exposure. NovoCure loses a notable name from its shareholder roster, which may increase share-price volatility and reduce passive support. The materiality is moderate: it does not alter fundamentals but could influence near-term trading dynamics.

Portfolio Manager

TL;DR – Institutional exit is noteworthy but not necessarily thesis-changing.

CII’s withdrawal means roughly 0.0 % of shares are now up for absorption by other investors. Although large holders exiting can pressure prices, liquidity in NVCR (111 M shares outstanding) may mitigate sustained impact. Absent additional earnings or operational data, the filing is limited to ownership structure. Investors should track subsequent 13F filings to see which funds absorb the float and whether other institutions follow suit.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

NovoCure Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

G6674U108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G6674U108

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NovoCure Ltd.
(b)	Address of issuer's principal executive offices: NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Jersey
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: G6674U108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 0 shares or 0.0% of the 111,485,634 shares believed to be outstanding.
(b)	Percent of class: 0.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Timothy J. Moon
Name/Title:	Vice President and Senior Counsel, Capital Research and Management Company
Date:	07/03/2025

FAQ

How many NovoCure (NVCR) shares does Capital International Investors now own?

The filing states 0 shares, representing 0.0 % of the outstanding class.

What is the event date for this Schedule 13G/A amendment?

The relevant event date is 06/30/2025; the document was signed on 07/03/2025.

Why did Capital International Investors file this amendment?

Because its ownership fell to 5 % or less, triggering an update under SEC Rule 13d-2.

How many shares were considered outstanding in the percentage calculation?

The filing references 111,485,634 NovoCure common shares outstanding.

Does Capital International Investors retain any voting or dispositive power over NVCR shares?

No. All categories—sole or shared voting and dispositive power—are reported as 0.

What type of filer is Capital International Investors in this document?

It is classified as an Investment Adviser (IA) under Rule 13d-1(b).